The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

根据发表在《英国药理学杂志》（British Journal of Pharmacology）上的研究结果，毛喉鞘蕊花素不仅能减缓白血病细胞的生长，还能提高化疗药物的疗效。萨里大学的研究团队发现，毛喉鞘蕊花素能激活蛋白磷酸酶2A（Protein Phosphatase 2A, PP2A），并降低几种与癌症相关的基因（MYC、HOXA9和HOXA10）的活性。

In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

本期看点：1. 抗半乳糖凝集素-9（galectin-9）单克隆抗体LYT-200用于治疗复发/难治性急性髓系白血病（AML）和高风险骨髓增生异常综合征（MDS），在一项早期临床试验中联合标准疗法，使患者的初步总生存期（OS）较同类患者延长近10个月。2.

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit ...

Review of current and emerging treatments for older adults with acute myeloid leukemia, highlighting venetoclax plus hypomethylating agents and future targeted therapy combinations in routine care.